Mergers & Acquisitions ·
Gyre Therapeutics filed an amendment to its May 4, 2026, Current Report to provide audited financial statements and…
GYREGyre Therapeutics, Inc.
Gyre Therapeutics filed an amendment to its May 4, 2026, Current Report to provide audited financial statements and unaudited pro forma combined financial information following its acquisition of Cullgen Inc. The merger, closed on May 4, 2026, was an all-stock transaction valuing Cullgen at approximately $300 million. Because both companies were controlled by GNI Japan, the transaction was treated as a combination of entities under common control, with assets and liabilities recognized at historical carrying amounts. Cullgen reported a net loss of $10.8 million and collaboration revenue of $15.4 million for the year ended December 31, 2025. Gyre Therapeutics is a biopharmaceutical company focused on developing medicines for diseases lacking effective therapeutic approaches.